ArticleJournal of inflammation research2026
Dermoscopic CIELab Colorimetry for Longitudinal Monitoring of Fixed Target Lesions in Psoriasis: Objective Quantification of Background Color and Vascular Density.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Objective longitudinal monitoring of a single psoriasis lesion remains underdeveloped. We evaluated the methodological feasibility of a quantitative fixed-target-lesion framework that derives continuous surface-color and vascular signals from dermoscopy, using CIELab as the measurement space rather than the clinical endpoint. Patients and Methods: This single-center retrospective longitudinal study included 28 patients with moderate-to-severe plaque psoriasis receiving biologic therapy (176 dermoscopic observations). Linear mixed-effects models (LMM) tested the longitudinal association between a* and PASI, and cumulative logit mixed models (CLMM) tested associations with ordinal dermoscopic scores. Data-driven a* thresholds were then applied unchanged to a separate mild-psoriasis cohort from the same center, device platform, and institutional database (BW cohort; 14 patients, 42 visit-level observations with concurrent scores) as a within-center transferability assessment. Results: a* was positively associated with PASI in the random-slope LMM (β = 0.928, p < 0.001). Data-driven a* tiers showed moderate agreement with expert background-color grading in the primary cohort (quadratic weighted κ = 0.538) and higher agreement in the unchanged-threshold BW assessment (κ = 0.722; ±1-level agreement 95.2%). The BW analysis was interpreted as within-center transferability, not external validation. Automated vessel-signal counts were associated with ordinal vessel-density scores (CLMM OR = 2.53 per SD, p < 0.001) and remained associated after adjustment for a* (OR = 2.13 per SD, p < 0.001). Exploratory treatment-group findings were treated as hypothesis-generating only. Conclusion: These findings provide proof-of-concept support for an objective, quantitative framework for monitoring fixed psoriatic target lesions. a* and rule-based vessel-signal counts are candidate lesion-level measures that may complement conventional scores, but clinical utility and cross-center or cross-device generalizability remain unestablished.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.